Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
CAR-T Immunotherapy Targeting CD19- ALL
2027. júl. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Multi-CAR-T Cells Targeting B Cell Lymphomas
2027. jún. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
CD19/22 Bi-specific CAR-T Cell Therapy
2027. jún. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)
2026. dec. 7.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL
2026. nov. 30.· NA · NOT_YET_RECRUITING· CTGOV
Publikáció
Immunohistochemical Classification and Prognostic Significance of Germinal Center-like and Memory Cell-like Subtypes of Follicular Lymphoma Using FOXP1, LMO2, CD22, and MUM1.
2026. szept. 26.· International journal of molecular sciences· PUBMED
Publikáció
A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.
2026. szept. 21.· Blood cancer discovery· PUBMED
Publikáció
Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.
2026. szept. 3.· JAMA oncology· PUBMED
Vizsgálat
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
2026. szept. 1.· PHASE1_PHASE2 · RECRUITING· CTGOV
Publikáció
CD22 regulates Aβ clearance in microglia through INPP5D signaling.
2026. júl. 28.· Frontiers in cellular neuroscience· PUBMED
Publikáció
Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy.
2026. júl. 8.· Journal for immunotherapy of cancer· PUBMED
Publikáció
Anti-CD19/CD22 CAR T cells in refractory immune thrombocytopenia of paediatric systemic lupus erythematosus.
2026. júl. 7.· Annals of the rheumatic diseases· PUBMED
Vizsgálat
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
2026. jún. 16.· PHASE2 · RECRUITING· CTGOV
Publikáció
SM03, a non-depleting anti-CD22 antibody, modulates B cell activation and immune crosstalk to attenuate autoimmunity.
2026. jún. 10.· Journal of translational autoimmunity· PUBMED
Publikáció
CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.
2026. jún. 5.· Journal for immunotherapy of cancer· PUBMED
Publikáció
Long-term complete remission and minimal side effects after CD19/CD22 CAR-T cell cocktail therapy in a living donor with DLBCL: A rare case report.
2026. jún. 2.· Cell transplantation· PUBMED
Vizsgálat
4SCAR-T Therapy Post CD19-targeted Immunotherapy
2026. jún. 1.· PHASE1_PHASE2 · TERMINATED· CTGOV
Publikáció
Unraveling cellular and molecular mechanisms of relapse in CD19/CD22 dual-targeting chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia.
2026. máj. 29.· Leukemia· PUBMED
Vizsgálat
Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
2026. máj. 13.· PHASE1 · RECRUITING· CTGOV
Publikáció
PD-L1-armored CD19/CD22 dual-targeted CAR-T cell co-infusion bridging to allogeneic hematopoietic stem cell transplantation achieves 7-year sustained remission in an adult patient with early relapsed, chemorefractory B-cell acute lymphoblastic leukemia: a case report.
2026. ápr. 27.· Frontiers in immunology· PUBMED
Publikáció
CD22-targeted immunotherapy for B-cell acute lymphoblastic leukemia progressing following CD19-targeted immunotherapy.
2026. ápr. 10.· NPJ precision oncology· PUBMED
Publikáció
Long-term outcomes of co-administration of CD19 and CD22 CAR-T cell therapy in pediatric patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
2026. ápr. 10.· Frontiers in medicine· PUBMED
Publikáció
TrkB promotes the neuronal secretion of soluble Siglec-2 (CD22) to mitigate microglial activation and alleviate depression-like behaviors in male mice.
2026. ápr. 1.· Molecular psychiatry· PUBMED
Publikáció
Disrupting CD22-cis-ligand interactions ameliorates type 1 diabetes and graft rejection by expanding regulatory B cells.
2026. márc. 24.· PLoS biology· PUBMED
Vizsgálat
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
2026. márc. 15.· PHASE1 · RECRUITING· CTGOV
Vizsgálat
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma
2026. márc. 10.· PHASE2 · COMPLETED· CTGOV
Publikáció
Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia.
2026. márc. 10.· Blood advances· PUBMED
Vizsgálat
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
2026. márc. 2.· PHASE1_PHASE2 · RECRUITING· CTGOV
Vizsgálat
Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL
2026. febr. 15.· EARLY_PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma.
2026. febr. 13.· Signal transduction and targeted therapy· PUBMED